IP Library Granted Patent US 9,750,934
Granted Patent B2
US 9,750,934 · App. 15/231,734 · Granted Sep 5, 2017

Treating bacteria with electric fields

Inventors: Yoram Palti (Haifa, IL); Moshe Giladi (Moshav Herut, IL)
Assignee: Novocure Limited
A61N1/205A61N1/0428A61N1/30A61N1/32A61N1/40C12N13/00A61B18/04A61N1/326
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,750,934
App. No.
15/231,734
Granted
Sep 5, 2017
Kind
B2
Abstract

Cells that are in the process division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective destruction of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time at particular frequencies with particular filed strengths. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages rapidly dividing cells like bacteria, but does not harm normal cells that are not dividing. Since the vulnerability of the dividing cells is strongly related to the alignment between the long axis of the dividing cells and the lines of force of the electric field, improved results can be obtained when the field is sequentially imposed in different directions.

Claims (14)

1. A method of selectively destroying or inhibiting growth of bacteria located within a target region, comprising the steps of:

capacitively coupling an AC electric field into the target region, wherein a frequency of the electric field is between 5 MHz and 20 MHz, wherein a strength of the electric field in at least a portion of the target region is between 2 V/cm and 100 V/cm, wherein the electric field has frequency characteristics that correspond to a vulnerability of the bacteria, and wherein the electric field is strong enough to damage a significant portion of the bacteria; and

repeating the coupling step until a therapeutically significant portion of the bacteria die.

2. The method of claim 1 , further comprising the step of delivering an antibiotic to the target region so that a therapeutically effective dose of the antibiotic is present in the target region while the coupling step is performed.

3. The method of claim 1 , wherein the strength of the electric field in at least a portion of the target region is between 5 V/cm and 20 V/cm.

4. The method of claim 1 , wherein the strength of the electric field in at least a portion of the target region is between 10 V/cm and 17 V/cm.

5. The method of claim 1 , wherein the frequency of the electric field is 10 MHz.

6. The method of claim 1 , wherein the electric field has a first orientation during a first interval of time and a second orientation during a second interval of time, wherein at least a portion of the first interval of time and the second interval of time are mutually exclusive.

7. The method of claim 1 , wherein the target region is a region within a live subject, and wherein the electric field is safe for the subject.

8. The method of claim 7 , further comprising the step of delivering an antibiotic to the target region so that a therapeutically effective dose of the antibiotic is present in the target region while the coupling step is performed.

9. The method of claim 7 , wherein the strength of the electric field in at least a portion of the target region is between 5 V/cm and 20 V/cm.

10. The method of claim 7 , wherein the strength of the electric field in at least a portion of the target region is between 10 V/cm and 17 V/cm.

11. The method of claim 7 , wherein the frequency of the electric field is 10 MHz.

12. The method of claim 7 , wherein the electric field has a first orientation during a first interval of time and a second orientation during a second interval of time, wherein at least a portion of the first interval of time and the second interval of time are mutually exclusive.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0335 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398 Recorded Aug 19, 2020
From: BPCR LIMITED PARTNERSHIP
To: NOVOCURE GMBH
Reel/Frame 053538/0623 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825 Recorded Apr 14, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052391/0549 →
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052383/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 050110/0098 →
SECURITY INTEREST Recorded May 6, 2019
From: NOVOCURE GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 050395/0398 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045284/0851 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045278/0825 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2017
From: PALTI, YORAM; GILADI, MOSHE
To: STANDEN LIMITED
Reel/Frame 043174/0532 →
CHANGE OF NAME Recorded Aug 2, 2017
From: STANDEN LIMITED
To: NOVOCURE LIMITED
Reel/Frame 043175/0292 →
Continuity (19)
Division 14731903 · Jun 5, 2015
Continuation 13782579 · Mar 1, 2013
Division 12958623 · Dec 2, 2010
Continuation In Part 12146918 · Jun 26, 2008
Continuation In Part 11111439 · Apr 21, 2005
Continuation In Part 11074318 · Mar 7, 2005
Continuation In Part 10315576 · Dec 10, 2002
Continuation In Part 10285313 · Oct 31, 2002
Continuation In Part 10263329 · Oct 2, 2002
Continuation In Part 10402327 · Mar 28, 2003
Continuation In Part 10204334
Continuation In Part 10288562 · Nov 5, 2002
Provisional Application 61266392 · Dec 3, 2009
Provisional Application 60947212 · Jun 29, 2007
Provisional Application 60565065 · Apr 23, 2004
Provisional Application 60639873 · Dec 27, 2004
Provisional Application 60183295 · Feb 17, 2000
Provisional Application 60338632 · Nov 6, 2001
Related Publication 20160346536A1 · Dec 1, 2016